feedback

Course Director

Nicola A. Hanania, MD, MS
Nicola A. Hanania, MD, MS

Airways Clinical Research Center
Baylor College of Medicine
Ben Taub Hospital
Houston, Texas

Faculty

Cedric
Cedric "Jamie" Rutland, MD

Rutland Medical Group
Newport Beach, California

Accredited by

Penn State College of Medicine

Activity Description and Educational Objectives

Approximately 20% of patients with asthma have uncontrolled, moderate to severe disease with recurrent exacerbations and persistent symptoms despite maximized standard-of-care controller therapy. Many of these patients have substantially reduced lung function and continue to lose lung function over time. About 50% of those with asthma have type 2 (T2) inflammation, which is mediated by cytokines such as interleukin (IL)-4, IL-5, and IL-13. Novel biologic agents that target T2 cytokines have shown efficacy and safety in these patients and are now available, with others in development, providing clinicians with more opportunities to personalize therapy for patients with severe asthma. In this activity, based on a recent symposium held in New Orleans, experts in pulmonology share actual patient stories to illustrate the recognition and burden of severe asthma in patients, as well as discuss best practices and strategies for managing this condition and facilitating effective collaboration with patients to actively engage them in their own care.

Upon completion of this activity, participants should be better able to:
  • Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies
  • Evaluate patients with asthma for symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies
  • Apply evidence-based guidelines and the latest clinical data when selecting treatment for patients with severe asthma
  • Use strategies to communicate effectively with patients about self-management and to improve inhaler technique, adherence, and overall quality of life in patients with severe asthma

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, allergy and immunology specialists, internists, and other clinicians involved in the care of patients with severe asthma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 29, 2019 - November 28, 2020
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair

Nicola A. Hanania, MD, MS
Associate Professor, Medicine-Pulmonary
Director, Airways Clinical Research Center
Member, Vice Chair of Research Group
Baylor College of Medicine
Director, Asthma and COPD Clinic
Ben Taub Hospital
Houston, Texas

Nicola A. Hanania, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron; and sanofi-aventis U.S. LLC.
Grant/Research Support from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Gossamer Bio; Novartis Pharmaceuticals Corporation; and sanofi-aventis U.S. LLC.
Speakers Bureau participant with AstraZeneca.

Faculty

Cedric "Jamie" Rutland, MD
CEO and Medical Director
Rutland Medical Group
Newport Beach, California

Cedric "Jamie" Rutland, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; and Genentech, Inc.
Speakers Bureau participant with AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech, Inc.; Regeneron; and sanofi-aventis U.S. LLC.

Medical Director

Mary Grecco
PVI, PeerView Institute for Medical Education

Mary Grecco has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Providership, Credit, and Support


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6552-20-T.

Providership

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.